Endogenex

Excited to present REGENT-1 study data at #ADA2025 this week in Chicago! New findings highlight the potential of our pulsed electric field (PEF) system to impact: ✅ Insulin sensitivity ✅ Beta cell function ✅ Dose responsivity #Type2Diabetes #Endogenex #ReCETStudy

Groundbreaking data at #DDW2025: AI-driven 3D spatial analysis reveals profound immune dysregulation and structural remodeling in T2D duodenums. Presented by @babudayyeh, the first-of-its-kind abstract marks a major advance in understanding diabetic duodenopathy. #T2D #duodenum

@babudayyeh presented 48-week outcomes from REGENT-1 study at #DDW2025, highlighting sustained improvement in insulin sensitivity & beta cell function following non-thermal PEF treatment of the duodenum. More to come from San Diego! #T2D #Endocrinology #diabetictduodenopathy

Mayo Clinic researchers are seeking volunteers ages 22-70 with a BMI between 27-40 for a randomized study of a device used for the treatment of type 2 diabetes. Contact DLRSTReCETinfo@mayo.edu or visit mayocl.in/40Tvhul for information.

Endogenex is adding to its leadership team. We are excited to announce Krissy Wright as the new Chief Financial Officer. prnewswire.com/news-releases/… #diabetes #GItwitter

Exciting News! Endogenex announces enrollment of the first patient in the ReCET Clinical Study. Led by Dr. Andre Teixeira at Orlando Health, this milestone marks a significant step in our mission to transform diabetes care. Read more in our press release below. 👇

A new paradigm suggesting that the integrative function of the duodenum in orchestrating the metabolic response is altered in metabolic diseases due to inflammation. This could represent a novel, potentially disease-modifying therapeutic target for type II diabetes. #diabetes2 #duodenum

@babudayyeh presenting cutting-edge data on endoscopic therapy approaches to #diabetes management A glimpse into the future! @DDWMeeting #DDW2024

Knowing the risk for Type 2 Diabetes & being diagnosed is half the battle. Today is World Diabetes Day. One in ten adults worldwide have diabetes, yet close to half are undiagnosed. #Endogenex supports awareness, prevention, & improved treatment options for people with #T2D

November is Diabetes Awareness Month-time to bring to light the challenges faced by people worldwide living with #diabetes. From prevention to the search for alternative treatment options, the #endogenex team supports improved outcomes & quality of life for those living with #T2D

EMINENT Clinical Study data being presented today at The European Association for the Study of Diabetes #EASD2023. @CelineBusch, MD et al. oral abstract highlights 12-month results in patients treated with the ReCET™ System cattendee.abstractsonline.com/meeting/10899/… #type2diabetes #GITwitter

ReCET Procedure in people with T2D was highlighted at the #ADA2023 . Data from REGENT-1 & EMINENT clinical studies outline early safety & feasibility experience. Thank you to Investigators from Australia, The Netherlands, & USA for your work in these studies.

eppro02.ativ.me/appinfo.php?pa… #ADA2023

eppro02.ativ.me/appinfo.php?pa… #ADA2023

Next up #ADA2023 from June 23 - 26 in San Diego. #type2diabetes #ReCET #diabetesmanagement #gastroenterology

#type2diabetes #ReCET #diabetesmanagement #gastroenterology #GItwitter #HereforDDW

Geoff Pardo and Stacey Pugh talk about Stacey’s career that began at the bedside as a trauma nurse and is now leading the charge at @Endogenex to take a new approach to Type 2 Diabetes treatment. Listen to the conversation: medtechmvp.com/media/medtech-…

@endogenex CEO, Stacey Pugh, shares her career experience in Med Tech, vision for Endogenex, and its mission for improving outcomes in people with Type 2 Diabetes. medtechmvp.com/media/medtech-…

#Endogenex, developer of a procedure for treating type 2 #diabetes, announced today that it appointed Stacey Pugh as its new CEO. More from @endogenex, HERE: drugdeliverybusiness.com/endogenex-form… #Surgical #Finance